# Calosyn Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/calosyn-pharma

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.calosynpharma.com
- Total disclosed funding: $5.2M
- Latest round: Series A (Jun 1, 2012)
- Investors on record: 4

## About

Calosyn Pharma is an innovative company specializing in advanced healthcare solutions. Their focus lies in developing effective pharmaceutical products to improve patient outcomes and enhance overall health.Calosyn Pharma operates primarily in the pharmaceutical sector, focusing on creating cutting-edge healthcare solutions. Founded in Boston, US, the company has undergone strategic growth since its inception. The CEO, Reid Grimes, leads the company, which has successfully raised USD 0.63 mn in Series A funding from BVM Capital as of June 2012, bringing the total funds raised to USD 0.63 mn and the current company valuation to USD 10.248 mn.Calosyn Pharma's primary offerings include a comprehensive digital platform that provides a wide array of video streaming services, focusing on adult entertainment content. This platform features various categories, such as horror, animation, science fiction, and romance, catering to diverse audience preferences. The services are designed to deliver high-quality, uncut content directly to end-users, thereby addressing the demand for accessible adult entertainment amidst evolving consumer preferences. The platform serves a global customer base, with significant penetration in the Asian market, particularly in regions with a strong demand for localized content in Cantonese and Mandarin. The content is available for streaming, making it convenient for users to access their preferred genres without geographical restrictions.The company’s revenue model is primarily subscription-based, enabling users to access premium content through monthly or annual payment plans. In addition to subscriptions, the company may engage in partnerships with content creators and distributors, ensuring a steady flow of diverse content while expanding its reach. Transactions typically occur directly between the platform and its users, with payments processed through secure online channels. The pricing structure encompasses various tiers, allowing consumers to choose plans that best suit their viewing habits, with potential additional revenue generated through advertising or affiliate deals. This multifaceted approach to revenue generation reinforces the company's position in the competitive adult entertainment industry.Calosyn Pharma plans to enhance its product offerings and expand into new geographic regions. The funding raised in June 2012 will support the development of new healthcare products aimed at increasing patient engagement and improving health outcomes. The company is targeting expansion into emerging markets in Asia by 2025, focusing on establishing a stronger presence in regions where demand for healthcare solutions is rising.

## Funding rounds

- Series A, Jun 1, 2012, $0.6M — BVM Capital
- Series A, Feb 29, 2012, $0.3M — BVM Capital
- Series A, Mar 26, 2010, $1.5M — BVM Capital
- Series A, Apr 30, 2009, $0.4M — BVM Capital, MB Venture Partners
- Series A, Oct 31, 2008, $0.9M — Research Corporation Technologies, BVM Capital, MB Venture Partners, Adams and Reese
- Series A, Mar 7, 2008, $1.5M — BVM Capital, MB Venture Partners

## Investors

- BVM Capital (https://capitalatlas.ai/funds/bvm-capital) — Series A
- MB Venture Partners (https://capitalatlas.ai/funds/mb-venture-partners) — Series A
- Research Corporation Technologies (https://capitalatlas.ai/funds/research-corporation-technologies) — Series A
- Adams and Reese — Series A